# A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

Study · id `cardio:ct-nct07318155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07318155](<https://clinicaltrials.gov/study/NCT07318155>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07318155

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT07318155. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-11 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT07318155, source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)
- Started: 2025-03-11 (actual) (ClinicalTrials.gov record NCT07318155, source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07318155, source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07318155, source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07318155, source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07318155-2026-04-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
- Condition: Coronary Artery Disease (CAD)
- Condition: Peripheral Arterial Disease
- Intervention (Drug): SRSD107
- Intervention (Drug): 0.9 % sodium chloride
- Lead sponsor: Sirius Therapeutics Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 3f1db91a64842f56c5a4c09347f769520d61d5b2aa8ced0d65e3cb5f54c7acb9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
